Ignite Creation Date:
2024-05-06 @ 12:16 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03719820
Status:
UNKNOWN
Last Update Posted:
2020-03-31
First Post:
2018-10-22
Brief Title:
Stroke Imaging Package Study of Intracranial Atherosclerosis SIPS-ICAS
Sponsor:
Wei-Hai Xu
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Stroke Imaging Package Study of Intracranial Atherosclerosis
Status:
UNKNOWN
Status Verified Date:
2020-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SIPS-ICAS
Brief Summary:
A prospective multicenter cohort study to explore the stroke mechanisms of symptomatic intracranial atherosclerosis the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus high-resolution magnetic resonance HR-MRI
Detailed Description:
1 First-ever stroke patients attributed to intracranial artery stenosis 50 or occlusion within 7 days after onset will be prospectively enrolled in our study and undergo new imaging technique package assessment at baseline
2 The imaging technique package includes conventional cranial MRI T1T2T2 FLAIRDWI cranial magnetic resonance angiography MRAhigh-resolution magnetic resonance HR-MRI and susceptibility weighted imaging SWI or T2-weighted imaging
3 Enrolled patients are recommended to receive aggressive medical management consisted of Aspirin 100 mg daily and Clopidogrel 75 mg daily for 3 months and Rosuvastatin 20mg daily for at least 6 months as well as traditional risk factors management
4 Patients were followed up for mRS score stroke recurrence medication compliance and laboratory examination including blood routine tests liver functions and creatine kinase et al at 3 months 6 months and 12 months after stroke onset Additionally patients are required to retake new HRMRI imaging of brain at 6 monthsRemote patient education by We-Chat will be performed
5 Our study aims to explore the stroke mechanisms of symptomatic intracranial atherosclerosis the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus HR-MRI
2 The imaging technique package includes conventional cranial MRI T1T2T2 FLAIRDWI cranial magnetic resonance angiography MRAhigh-resolution magnetic resonance HR-MRI and susceptibility weighted imaging SWI or T2-weighted imaging
3 Enrolled patients are recommended to receive aggressive medical management consisted of Aspirin 100 mg daily and Clopidogrel 75 mg daily for 3 months and Rosuvastatin 20mg daily for at least 6 months as well as traditional risk factors management
4 Patients were followed up for mRS score stroke recurrence medication compliance and laboratory examination including blood routine tests liver functions and creatine kinase et al at 3 months 6 months and 12 months after stroke onset Additionally patients are required to retake new HRMRI imaging of brain at 6 monthsRemote patient education by We-Chat will be performed
5 Our study aims to explore the stroke mechanisms of symptomatic intracranial atherosclerosis the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus HR-MRI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None